Press Releases March 26, 2026 06:30 AM

BOSS Zhipin Repurchases 748,460 Shares; Total Repurchases Amount to Over RMB480 Million in 2026

KANZHUN LIMITED intensifies share repurchase program with over RMB480 million deployed in 2026

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
BZ

KANZHUN LIMITED, trading as BOSS Zhipin on Nasdaq, announced ongoing execution of its share repurchase program, spending approximately RMB34.4 million to buy back 748,460 ordinary shares on March 25, bringing total repurchases in 2026 to over RMB480 million. This action reflects the company's commitment to enhance shareholder value.

BOSS Zhipin Repurchases 748,460 Shares; Total Repurchases Amount to Over RMB480 Million in 2026
BZ
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • KANZHUN LIMITED repurchased 748,460 shares using RMB34.4 million on March 25, 2026.
  • Total share repurchases in 2026 have surpassed RMB480 million.
  • The repurchase program signals strong commitment to shareholder returns and confidence in company valuation.

BEIJING, March 26, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HK: 2076) today announced the continued execution of its share repurchase program, utilizing around RMB34.4 million to repurchase 748,460 ordinary shares on March 25. Year-to-date in 2026, the Company has deployed over RMB480 million toward share repurchases. This move underscores the Company's ongoing commitment to shareholder returns.


Risks

  • Future share price volatility may affect the company's market capitalization and repurchase impact.
  • Large capital allocation to buybacks may limit funds available for operational growth or strategic investments.
  • Market conditions or regulatory changes could influence future repurchase activities or company performance.

More from Press Releases

Silvaco CEO Dr. Walden “Wally” Rhines Inducted into the National Academy of Engineering Oct 2, 2026 Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A) Oct 2, 2026 Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026 Oct 1, 2026 New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program Oct 1, 2026 FEMSA Schedules Conference Call to Discuss Third Quarter Financial Results Oct 1, 2026